Author： Levitzki Alexander
Publisher： Humana Press, Inc
ISSN： 1357-0560
Source： Medical Oncology, Vol.14, Iss.2, 1997-06, pp. : 83-89
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
With the advance in the molecular understanding of cancers and proliferative disorders new approaches to managing these diseases may become feasible. It has been recognized that a key feature of these diseases is the pathological alteration in the molecular machineries of signalling pathways. This recognition which began to emerge in the early 1980s induced us to explore the possibility of targetting the aberrant signalling pathways for disease therapy. I now present evidence for the validity of the approach.
Related content
Signal transduction of vitamin K3 for pancreas cancer therapy
Oncology Reviews, Vol. 5, Iss. 1, 2011-03 ,pp. :
Access to resources
Recommend
Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 7, Iss. 6, 2007-11 ,pp. :
Signal Transduction Inhibitors
By Grunicke H.
European Journal of Cancer, Vol. 31, Iss. 5, 1995-01 ,pp. :
Signal transduction targets in invasion
By Alessandro Riccardo Kohn Elise
Clinical and Experimental Metastasis, Vol. 19, Iss. 3, 2002-05 ,pp. :